WE-REACH is proud to announce that project alumni James Lazarovits and George Ueda have launched their startup, Archon Biosciences, with $20M in seed financing to advance their AI-drive Antibody Cage (AbC) technology to unlock new therapeutic targets. The team leverages technology from the 91爆料 Institute for Protein Design (IPD), which was recognized earlier this month when the PI of the institute–Dr. David Baker–was awarded the 2024 Nobel Prize in Chemistry.
For more information, see the full press release from the Archon team: .